Prevalence of Colistin Resistance in Clinical Isolates of : a Systematic Review and Meta-analysis

Overview

Journal Front Microbiol

Specialty Microbiology

Date 2024 Oct 30

PMID 39473844

Authors

Negar Narimisa

Abbasali Keshtkar

Leila Dadgar-Zankbar

Narjess Bostanghadiri

Yasaman Rouein Far

Soheila Shahroodian

Abed Zahedi Bialvaei

Shabnam Razavi

Affiliations

Soon will be listed here.

Abstract

Objective: The emergence of resistance to colistin, the last resort for treating severe infections caused by , poses a significant threat to public health. This meta-analysis aimed to investigate the prevalence of colistin resistance in clinical isolates of

Method: A comprehensive search of MEDLINE (PubMed), Web of Science, and Scopus databases was conducted to identify relevant articles published until December 2023. Subsequently, a meta-analysis was performed using Stata software to examine the pooled prevalence of colistin resistance and to conduct subgroup analyses.

Results: A total of 619 studies were included in the meta-analysis, revealing a global prevalence of colistin resistance of 1% among all isolates. Furthermore, cystic fibrosis patients exhibited the highest resistance to colistin, with a prevalence of 7% among the examined diseases.

Conclusion: The increase in colistin resistance in in recent years from 2% (in the period of 2006-2010) to 5% (in the period of 2020-2023) underscores the need for implementing infection prevention programs, using appropriate treatment regimens, and disseminating comprehensive information on antimicrobial resistance patterns. These measures are crucial for addressing this growing public health concern.

Citing Articles

Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.

Dallal Bashi Y, Mairs R, Murtadha R, Kett V Pharmaceutics. 2025; 17(1).

PMID: 39861758 PMC: 11768398. DOI: 10.3390/pharmaceutics17010111.

High-risk clones harboring β-lactamases: 2024 update.

Flores-Vega V, Partida-Sanchez S, Ares M, Ortiz-Navarrete V, Rosales-Reyes R Heliyon. 2025; 11(1):e41540.

PMID: 39850428 PMC: 11754179. DOI: 10.1016/j.heliyon.2024.e41540.

References

Karlowsky J, Lob S, Hawser S, Kothari N, Siddiqui F, Alekseeva I . Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21. JAC Antimicrob Resist. 2023; 5(4):dlad098. PMC: 10416811. DOI: 10.1093/jacamr/dlad098. View

Vosahlikova S, Drevinek P, Cinek O, Pohunek P, Maixnerova M, Urbaskova P . High genotypic diversity of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis in the Czech Republic. Res Microbiol. 2007; 158(4):324-9. DOI: 10.1016/j.resmic.2007.02.003. View

Abed W, Mohammed Kareem S . Molecular detection of gyrA and mexA genes in Pseudomonas aeruginosa. Mol Biol Rep. 2021; 48(12):7907-7912. DOI: 10.1007/s11033-021-06820-0. View

Chew K, Octavia S, Ng O, Marimuthu K, Venkatachalam I, Cheng B . Challenge of drug resistance in Pseudomonas aeruginosa: clonal spread of NDM-1-positive ST-308 within a tertiary hospital. J Antimicrob Chemother. 2019; 74(8):2220-2224. DOI: 10.1093/jac/dkz169. View

Hu Y, Liu C, Wang Q, Zeng Y, Sun Q, Shu L . Emergence and Expansion of a Carbapenem-Resistant Pseudomonas aeruginosa Clone Are Associated with Plasmid-Borne and Virulence-Related Genes. mSystems. 2021; 6(3). PMC: 8269210. DOI: 10.1128/mSystems.00154-21. View

Parsa P, Amirmozafari N, Nowruzi B, Bahar M . Molecular characterization of polymorphisms among strains isolated from burn patients' wounds. Heliyon. 2020; 6(12):e05041. PMC: 7758517. DOI: 10.1016/j.heliyon.2020.e05041. View

Kristof K, Adamkova V, Adler A, Gospodarek-Komkowska E, Rafila A, Billova S . In vitro activity of ceftazidime-avibactam and comparators against Enterobacterales and Pseudomonas aeruginosa isolates from Central Europe and Israel, 2014-2017 and 2018. Diagn Microbiol Infect Dis. 2021; 101(1):115420. DOI: 10.1016/j.diagmicrobio.2021.115420. View

Descours G, Desmurs L, Hoang T, Ibranosyan M, Baume M, Ranc A . Evaluation of the Accelerate Pheno™ system for rapid identification and antimicrobial susceptibility testing of Gram-negative bacteria in bloodstream infections. Eur J Clin Microbiol Infect Dis. 2018; 37(8):1573-1583. DOI: 10.1007/s10096-018-3287-6. View

Walkty A, Lagace-Wiens P, Adam H, Baxter M, Karlowsky J, Mulvey M . Antimicrobial susceptibility of 2906 Pseudomonasaeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008-2015. Diagn Microbiol Infect Dis. 2017; 87(1):60-63. DOI: 10.1016/j.diagmicrobio.2016.10.003. View

10.

Costa Junior S, da Silva W, da Silva A, Maciel M, Cavalcanti I . Synergistic Effect between Usnic Acid and Polymyxin B against Resistant Clinical Isolates of . Evid Based Complement Alternat Med. 2020; 2020:9852145. PMC: 7441413. DOI: 10.1155/2020/9852145. View

11.

El-Mokhtar M, Hetta H . Ambulance vehicles as a source of multidrug-resistant infections: a multicenter study in Assiut City, Egypt. Infect Drug Resist. 2018; 11:587-594. PMC: 5926072. DOI: 10.2147/IDR.S151783. View

12.

Walkty A, DeCorby M, Lagace-Wiens P, Karlowsky J, Hoban D, Zhanel G . In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011; 55(6):2992-4. PMC: 3101411. DOI: 10.1128/AAC.01696-10. View

13.

Czekajlo-Kolodziej U, Giedrys-Kalemba S, Medrala D . Phenotypic and genotypic characteristics of Pseudomonas aeruginosa strains isolated from hospitals in the north-west region of Poland. Pol J Microbiol. 2007; 55(2):103-12. View

14.

Mohamed A, Omar N, Osman M, Mohamud H, Eraslan A, Gur M . Antimicrobial Resistance and Predisposing Factors Associated with Catheter-Associated UTI Caused by Uropathogens Exhibiting Multidrug-Resistant Patterns: A 3-Year Retrospective Study at a Tertiary Hospital in Mogadishu, Somalia. Trop Med Infect Dis. 2022; 7(3). PMC: 8948891. DOI: 10.3390/tropicalmed7030042. View

15.

Licata F, Quirino A, Pepe D, Matera G, Bianco A, Group C . Antimicrobial Resistance in Pathogens Isolated from Blood Cultures: A Two-Year Multicenter Hospital Surveillance Study in Italy. Antibiotics (Basel). 2020; 10(1). PMC: 7824585. DOI: 10.3390/antibiotics10010010. View

16.

Franco M, Caiaffa-Filho H, Burattini M, Rossi F . Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital. Clinics (Sao Paulo). 2010; 65(9):825-9. PMC: 2954731. DOI: 10.1590/s1807-59322010000900002. View

17.

Bourgi J, Said J, Yaakoub C, Atallah B, Al Akkary N, Sleiman Z . Bacterial infection profile and predictors among patients admitted to a burn care center: A retrospective study. Burns. 2020; 46(8):1968-1976. DOI: 10.1016/j.burns.2020.05.004. View

18.

Bonyadi P, Saleh N, Dehghani M, Yamini M, Amini K . Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis. Microb Pathog. 2022; 165:105461. DOI: 10.1016/j.micpath.2022.105461. View

19.

Kohira N, Hackel M, Oota M, Takemura M, Hu F, Mizuno H . In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020. J Glob Antimicrob Resist. 2022; 32:181-186. DOI: 10.1016/j.jgar.2022.11.017. View

20.

Pancholi P, Carroll K, Buchan B, Chan R, Dhiman N, Ford B . Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis. J Clin Microbiol. 2018; 56(4). PMC: 5869823. DOI: 10.1128/JCM.01329-17. View